Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.57 |
| ▸ | NEK1 | Q96PY6 | 5/20 | 0.55 |
| ▸ | AXL | P30530 | 4/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | MARK3 | P27448 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857267 | 1.00 | AAK1 (0.57) | AAK1NEK1AXLNTRK1DYRK3 | |
| SCHEMBL413487 | 0.90 | AAK1 (0.49) | AAK1NEK1AXLNTRK1DYRK3 | |
| SCHEMBL413488 | 0.90 | AAK1 (0.49) | AAK1NEK1AXLNTRK1DYRK3 | |
| SCHEMBL411335 | 0.89 | AAK1 (0.48) | AAK1NEK1AXLNTRK1DYRK3 | |
| SCHEMBL411334 | 0.89 | AAK1 (0.48) | AAK1NEK1AXLNTRK1DYRK3 | |
| SCHEMBL856965 | 0.87 | AAK1 (0.48) | AAK1NEK1AXLNTRK1PLCG1 | |
| SCHEMBL856813 | 0.87 | PAK1 (0.48) | AAK1NEK1AXLPLCG1RIPK1 | |
| SCHEMBL858329 | 0.87 | AAK1 (0.67) | AAK1NEK1AXLNTRK1DYRK3 | |
| SCHEMBL857394 | 0.84 | AAK1 (0.64) | AAK1NEK1AXLNTRK1DYRK3 | |
| SCHEMBL414830 | 0.84 | BRD4 (0.48) | AAK1NEK1AXLNTRK1DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067434-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | PLEXXIKON INC | 2010-12-23 | — | — | US | claimed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | RET, GFRA3, GFRA1 | AAK1 2341/4885NEK1 1594/4885AXL 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.